Cancer Survivor Replaced High-Dose Opioids With Medical Cannabis for Pain

A 27-year-old Ewing sarcoma survivor with intractable pain completely replaced high-dose opioids with THC-rich cannabis within 4 weeks, maintaining pain control and unexpectedly resolving a chronic infection over 9 months.

De Virgilio Suglia, Cesare et al.·Journal of cannabis research·2026·lowclinical-observation
RTHC-08215Clinical Observationlow2026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
clinical-observation
Evidence
low
Sample
Not reported

What This Study Found

After initiating THC-rich cannabis (Bedrocan, 22% THC, 1% CBD, 1g/day), the patient's pain dropped from VAS 9-10 to VAS 2-3. Complete opioid discontinuation occurred within 4 weeks (from 120mg/day morphine equivalents). Over 9 months, a chronic draining fistula closed completely and CRP dropped from 9.6 to 2.3 mg/dL.

Key Numbers

Pain: VAS 9-10 → VAS 2-3. Opioids: 120mg/day morphine equivalents → 0 within 4 weeks. CRP: 9.6 → 2.3 mg/dL. Cannabis: Bedrocan 22% THC, 1% CBD, 1g/day. Follow-up: 9 months. Chronic fistula: complete closure. No adverse effects reported.

How They Did This

Single case report of a 27-year-old male long-term Ewing sarcoma survivor with chronic multi-drug resistant periprosthetic osteomyelitis. Supervised medical cannabis therapy initiated after refusing amputation. 9-month follow-up tracking pain, opioid use, inflammation markers, and fistula status.

Why This Research Matters

This case demonstrates that medical cannabis may enable opioid-free pain management in complex cancer cases. The unexpected resolution of chronic infection and inflammation raises intriguing questions about cannabinoid immunomodulatory effects beyond pain relief.

The Bigger Picture

The opioid crisis makes alternatives for cancer pain urgent. This case is remarkable not just for opioid replacement but for the apparent anti-inflammatory effect — the resolution of a chronic multi-drug-resistant infection that had persisted for over a decade is unexpected and warrants investigation.

What This Study Doesn't Tell Us

Single case report — cannot prove causation. Spontaneous improvement cannot be excluded. No blinding or control. The patient's strong belief in cannabis may contribute to pain improvement (placebo effect). Infection resolution may be coincidental.

Questions This Raises

  • ?Can THC-rich cannabis consistently replace opioids in cancer pain?
  • ?Did cannabis truly contribute to infection resolution, or was it coincidental?
  • ?Should controlled trials investigate cannabinoid immunomodulation in chronic infections?

Trust & Context

Key Stat:
Evidence Grade:
Single case report — the most dramatic outcome possible but cannot establish causation or generalize to other patients.
Study Age:
Published in 2026, reporting treatment initiated in January 2025 with 9 months of follow-up.
Original Title:
Ewing sarcoma-related pain: potential role of medical cannabis monotherapy in symptom management - a case report.
Published In:
Journal of cannabis research, 8(1), 21 (2026)
Database ID:
RTHC-08215

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Can medical cannabis replace opioids for cancer pain?

In this single case, yes — a patient with severe cancer-related pain completely stopped opioids within 4 weeks of starting medical cannabis. However, one case can't prove this would work broadly, and controlled trials are needed.

Did cannabis help with the infection too?

The timing is suggestive — a chronic draining infection that persisted for years resolved after cannabis initiation, with inflammation markers dropping. However, this could be coincidental, and the authors cannot establish causation from one case.

Read More on RethinkTHC

Cite This Study

RTHC-08215·https://rethinkthc.com/research/RTHC-08215

APA

De Virgilio Suglia, Cesare; Spaccavento, Felice Antonio; Turco, Fabio; De Trizio, Angela; Giannuzzi, Rossella; Tafuri, Silvio. (2026). Ewing sarcoma-related pain: potential role of medical cannabis monotherapy in symptom management - a case report.. Journal of cannabis research, 8(1), 21. https://doi.org/10.1186/s42238-026-00388-x

MLA

De Virgilio Suglia, Cesare, et al. "Ewing sarcoma-related pain: potential role of medical cannabis monotherapy in symptom management - a case report.." Journal of cannabis research, 2026. https://doi.org/10.1186/s42238-026-00388-x

RethinkTHC

RethinkTHC Research Database. "Ewing sarcoma-related pain: potential role of medical cannab..." RTHC-08215. Retrieved from https://rethinkthc.com/research/de-2026-ewing-sarcomarelated-pain-potential

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.